Rat anti Rituximab:FITC,clone MB2A4
文献支持

Rat anti Rituximab:FITC,clone

MB2A4
收藏
  • 询价
  • BIO-RAD已认证
  • MCA2260F
  • 2025年10月17日
  • F
  • 详细信息
  • 文献和实验
  • 技术资料
  • 免疫原

    F(ab)2 fragment of Rituximab

  • 亚型

    IgG2a

  • 形态

    Purified IgG - liquid

  • 克隆性

    Monoclonal Antibody

  • 标记物

    FITC

  • 保质期

    自发货之日起 12 个月

  • 目录编号

    MB2A4

  • 供应商

    伯乐生命医学产品(上海)有限公司

  • 应用范围

    F

  • 浓度

    IgG concentration 0.1 mg/ml

  • 抗体名

    Rituximab antibody | MB2A4

  • 规格

    0.1 mg

Rat Anti-Rituximab Antibody, clone MB2A4, is an anti-idiotypic antibody that recognizes the monoclonal antibody drug rituximab. The antibody can be used to measure the levels of rituximab and biosimilar products in bioanalytical assays. Rat Anti-Rituximab Antibody also recognizes ocrelizumab, a second-generation humanized anti-CD20 antibody that binds to an epitope on CD20 that is identical or overlapping with the rituximab epitope. Clone MB2A4 has been used in ELISA to monitor the levels of rituximab in patient serum following therapy (Cragg et al. 2004 and Hampson et al. 2010).

Clone MB2A4 has been used to detect rituximab bound to the surface of the Raji B cell line, however detection of rituximab bound in vivo to B-CLL cells has not been demonstrated. It is possible that complement deposition on rituximab opsonised cells inhibits binding of the Anti-Rituximab Antibody to cell bound rituximab (Beum et al. 2004). Inhibition experiments carried out with Daudi cells demonstrated that this antibody is inhibitory at a ratio of 5:1 antibody:rituximab, but does not inhibit rituximab binding to CD20 at a ratio of 1:1.

Rituximab (reference product branded as Rituxan) is a chimeric mouse/human monoclonal antibody approved for the treatment of certain autoimmune diseases and cancer, including non-Hodgkin's lymphoma, chronic lymphocytic leukemia and rheumatoid arthritis. The antibody is specific for the cell surface protein CD20, which is widely expressed on B cells. Through three different mechanisms of action it eliminates B cells from the body, enabling the development of a new population of healthy B cells.

View a summary of all Anti-Rituximab Antibodies.


储存信息

This product is shipped at ambient temperature. It is recommended to aliquot and store at -20°C on receipt. When thawed, aliquot the sample as needed. Keep aliquots at 2-8°C for short term use (up to 4 weeks) and store the remaining aliquots at -20°C.

Avoid repeated freezing and thawing as this may denature the antibody. Storage in frost-free freezers is not recommended. This product is photosensitive and should be protected from light.


应用

This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit the antibody protocols page.
Application Name Verified Min Dilution Max Dilution
Flow Cytometry Neat
Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.
Flow Cytometry
Use 10μl of the suggested working dilution to label 106 cells in 100μl


风险提示:丁香通仅作为第三方平台,为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全,合理判断,谨慎选购商品,商家和用户对交易行为负责。对于医疗器械类产品,请先查证核实企业经营资质和医疗器械产品注册证情况。

图标文献和实验
该产品被引用文献

References for Rituximab antibody

  1. Cragg, M. S. et al. (2004) A new anti-idiotype antibody capable of binding rituximab on the surface of lymphoma cells.
    Blood. 104:2540-2
  2. Cragg, M.S. et al. (2004) Apparent modulation of CD20 by rituximab: an alternative explanation.
    Blood. 103 (10): 3989-90; author reply 3990-1.
  3. Pers, J.O. et al. (2007) BAFF-modulated repopulation of B lymphocytes in the blood and salivary glands of rituximab-treated patients with Sjögren's syndrome.
    Arthritis Rheum. 56: 1464-77.
  4. Hampson, G. et al. (2010) Validation of an ELISA for the determination of rituximab pharmacokinetics in clinical trials subjects.
    J Immunol Methods. 360 (1-2): 30-8.
  5. Blasco, H. et al. (2007) Evaluation of a peptide ELISA for the detection of rituximab in serum.
    J Immunol Methods.325: 127-39.
  6. Daydé, D. et al. (2009) Tumor burden influences exposure and response to rituximab: pharmacokinetic-pharmacodynamic modeling using a syngeneic bioluminescent murine model expressing human CD20.
    Blood. 113: 3765-72.
  7. Aung, T. et al. (2011) Exosomal evasion of humoral immunotherapy in aggressive B-cell lymphoma modulated by ATP-binding cassette transporter A3.
    Proc Natl Acad Sci U S A. 108: 15336-41.
  8. Schmidt, E. et al. (2009) Immunogenicity of rituximab in patients with severe pemphigus.
    Clin Immunol. 132: 334-41.
图标技术资料

暂无技术资料 索取技术资料

同类产品报价

产品名称
产品价格
公司名称
报价日期
询价
伯乐生命医学产品(上海)有限公司 Bio-Rad Laboratories
2025年10月17日询价
¥6900
深圳欣博盛生物科技有限公司
2025年05月22日询价
¥6900
GeneTex
2025年05月20日询价
¥1028
上海联迈生物工程有限公司
2025年05月05日询价
询价
广州东锐科技有限公司
2025年07月26日询价
文献支持
Rat anti Rituximab:FITC,clone MB2A4
询价